Serostim Accelerates Recovery in U.S. Males with Lymphoma Post-Chemotherapy: Multicenter Cohort Study
Reading Time: < 1 minute Introduction Lymphoma, a heterogeneous group of hematologic malignancies, disproportionately affects American males, with non-Hodgkin lymphoma (NHL) incidence rates reaching 20.6 per 100,000 among white men aged 65 and older, per Surveillance, Epidemiology, and End Results (SEER) data. Cytotoxic chemotherapy, the cornerstone of treatment, induces profound catabolism, immunosuppression, and muscle wasting, prolonging recovery and elevating relapse risks. Traditional supportive therapies—nutritional supplementation, erythropoiesis-stimulating agents, and physical rehabilitation—yield modest gains, with median recovery times exceeding 6 months. Serostim (somatropin), a recombinant human growth hormone (rhGH), modulates anabolism via insulin-like growth factor-1 (IGF-1) upregulation, potentially accelerating hematopoietic reconstitution and lean body mass restoration. This...


